Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240037/S003

VENTANA MET (SP44) RxDx Assay

Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) · Decision date Oct 23, 2026

MEDTECHLEDGER EXPLANATIONP240037/S003

What did the FDA approve?

FDA approved a labeling change for the VENTANA MET (SP44) RxDx Assay under supplement S003. The change adds results from supplemental data in Post-Approval Study Report P240037/R004 concerning use of SurePath for preparation of cytology specimens.

This is a Normal 180 Day Track supplement with no user fee, classified as a Labeling Change - PAS. The decision does not represent a new approval of the assay system itself. The statement reports the purpose of the labeling update but does not independently establish safety or clinical effectiveness.

FDA approval order statement

Approval to update the labeling for the VENTANA MET (SP44) RxDx Assay to include results of supplemental data provided in the Post-Approval Study (PAS) Report P240037/R004 for utilization of SurePath for preparation of cytology specimens.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Pathology
Decision date
Oct 23, 2026
FDA change category
Labeling Change - PAS

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240037/S003
Regulatory pathway
PMA supplement
Product code
SER
Decision code
APPR
Decision date
Oct 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry Assay, Antibody, MET.

Product code
SER
FDA device class
3

For the original device and its historical approval scope, see PMA P240037. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240037 · Original PMA

    VENTANA MET (SP44) RxDx Assay

  2. P240037/S003 received

    Application receipt date recorded by FDA.

  3. P240037/S003 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P240037. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240037

Product / regulatory recordCompanyPathwayDecision dateSource
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)PMA approvalMay 14, 2025FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1910 E. Innovation Park Dr., Tucson, AZ, 85755

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records